Study type: In vitro · Status: Verified against declared source

Human cathelicidin, LL-37, inhibits respiratory syncytial virus infection in polarized airway epithelial cells

2016

Study scale: The cationic peptide cathelicidin, LL-37, is an important part of the early innate immune response to bacterial infection.

Abstract only: Open source record

Product or molecular entity relationships

LL-37: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Differences in the efficacy of LL-37 at reducing RSV infection under prophylactic and therapeutic conditions may in part be ascribed to differences in the method of peptide exposure.

Scale or participants

The cationic peptide cathelicidin, LL-37, is an important part of the early innate immune response to bacterial infection.

Key findings

Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract illness in young children worldwide.

Limitations and uncertainty

Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract illness in young children worldwide.

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.